| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Mereo BioPharma Group plc$0.34
+0.01 (+3.33%)
C 52Pipeline Score Fair Value Biotech · Commercial
Market Cap
44.42 M
EPS
-0.22
P/E Ratio
-
Value Trade
2.48 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
4.75 M
Operating CF
-4.31 M
Total Assets
40.61 M
Total Liabilities
6.56 M
Equity
34.05 M
D/E Ratio
12,345
10 %
Week
-13.46 %
1 Month
-36.11 %
3 Month
-84.54 %
6 Month
-91.52 %
5 Year
-94.23 %
All Time
Cash Data
Cash Position
36.22 M
Monthly Burn
1.44 M
Runway
23.2 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
1.36 M
52 Week Range
0.20 - 3.05
% held by Insiders
0 %
% held by Institutions
47.84 %
Enterprise Value
8.20 M
Total Shares
159.62 M
Short %
3.35 %
Float Shares
159.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Mereo BioPharma Group plc
410Total events
2Upcoming
112Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 2
Event history 408
Q3 2026
◆Trial InitiationvantictumabTrial
Phase 2 trial initiation expected in second half of 2026
autosomal dominant osteopetrosis Type 2source ↗
May 12, 2026
◆Full ResultssetrusumabClinical Data
Further analyses of data from Cosmic Phase 3 study completed
osteogenesis imperfectasource ↗
May 12, 2026
◆FDA Feedback ReceivedsetrusumabFDA Meeting
Initiated regulatory interactions with agencies for setrusumab in pediatric OI
osteogenesis imperfectasource ↗
May 12, 2026
◆Partnership / LicensealvelestatApprovedCorporate
Engaged in discussions with potential partners for alvelestat Phase 3 development
alpha-1 antitrypsin deficiency-associated lung diseasesource ↗
Apr 6, 2026
Q2 2026
▲Trial InitiationvantictumabTrial
shibio plans to initiate Phase 2 trial of vantictumab in ADO2
autosomal dominant osteopetrosis Type 2source ↗
Mar 19, 2026
◆Additional DatasetrusumabClinical Data
Additional data analyses from Orbit and Cosmic Phase 3 studies ongoing
osteogenesis imperfectasource ↗
Jan 14, 2026
◆Oral PresentationPresentation
Dr. Denise Scots-Knight presents at 44th Annual J.P. Morgan Healthcare Conference
Drug Pipeline Intelligence
C52
Pipeline Score $71M
Pipeline ValueFair Value
Valuation Signal16
Drugs Scored1.6x
rNPV / MCap Top 78%
Micro Cap (rank 202 of 912)
Percentile RankMereo BioPharma Group plc carries a moderate pipeline score (52/100), with $5.2B risk-adjusted pipeline value, led by Demcizumab in Locally Advanced or Metastatic Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Demcizumab Small molecule | Pancreatic Cancer | Phase 2 | NCT01189929 | 19% | $2.0B | COMPLETED | 264 | - | - | Dec 1, 2016 | - | Sep 9, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
setrusumab Breakthrough | osteogenesis imperfecta | Phase 3 | 2026-03-19 | statistically significant improvements in bone mineral density; compelling reductions in vertebral fractures; statistically significant improvements in PROs of disease pain and daily activity in pediatric and teenage patients Read More | Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $ Read More | |
setrusumab Breakthrough | osteogenesis imperfecta | Phase 3 | 2026-03-19 | statistically significant improvements in bone mineral density; compelling reductions in vertebral fractures; statistically significant improvements in PROs of disease pain and daily activity in pediatric and teenage patients Read More | Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $ Read More | |
setrusumab Breakthrough | osteogenesis imperfecta | Phase 3 | 2026-03-19 | statistically significant improvements in bone mineral density; compelling reductions in vertebral fractures; statistically significant improvements in PROs of disease pain and daily activity in pediatric and teenage patients Read More | Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $ Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MREO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MREO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MREOMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Mereo BioPharma reported its Q1 2026 financial results, highlighting ongoing clinical developments. The company is engaging with regulatory agencies regarding setrusumab for pediatric osteogenesis imperfecta. Alvelestat is poised to enter Phase 3 development, while vantictumab is set for a Phase 2 trial in osteopetrosis. The financial outlook remains stable with a cash position of $36.2 million.
Read more →MREOMEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Regarding Their Rights
A class action lawsuit has been filed against Mereo BioPharma Group plc in the U.S. District Court for the Southern District of New York. The suit claims that the company misled investors about the anticipated outcomes of its Phase 3 ORBIT and COSMIC studies for setrusumab in Osteogenesis Imperfecta. Following the disclosure that neither study met its primary endpoints, Mereo's stock plummeted over 87% in value. Investors are encouraged to contact the law firm for potential participation in the lawsuit.
Read more →MREOMereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO
Mereo BioPharma Group plc is facing a class action lawsuit for violating securities laws. The lawsuit claims that the company misled investors regarding its Phase 3 ORBIT and COSMIC programs, which did not meet their clinical endpoints. Shareholders who purchased shares during the specified class period are urged to contact the DJS Law Group for potential recovery. The deadline for participation in the lawsuit is April 6, 2026.
Read more →MREOMEREO LAWSUIT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Before April 6th
A class action lawsuit has been filed against Mereo BioPharma Group plc, concerning misrepresentations related to the Phase 3 ORBIT and COSMIC studies for setrusumab in Osteogenesis Imperfecta. The lawsuit claims that these studies did not achieve their primary endpoints, leading to significant losses for investors. Following the disappointing results, Mereo's stock saw a dramatic decline of over 87.7%. The legal firm Bragar Eagel & Squire is urging affected investors to contact them before the April 6, 2026 deadline to join the lawsuit.
Read more →MREOMereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $
Mereo BioPharma reported its financial results for the full year 2025, highlighting ongoing analyses from the Phase 3 studies of setrusumab for osteogenesis imperfecta. Although primary endpoints were not met, secondary endpoints demonstrated significant improvements in bone mineral density. The company is actively pursuing partnerships for a Phase 3 study of alvelestat while its revised financial roadmap now supports operations into mid-2027. However, the company reported a net loss and a decrease in cash reserves, which may pose challenges moving forward.
Read more →MREOMereo BioPharma Group plc Class Action: The Gross Law Firm Reminds Mereo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – MREO
Mereo BioPharma Group plc is currently facing a class action lawsuit as announced by The Gross Law Firm. The lawsuit alleges that the company provided misleading statements about its Phase 3 ORBIT and COSMIC clinical trials, which failed to achieve their primary endpoints of reducing the annualized clinical fracture rate. Following the release of this information, Mereo's stock price plummeted by more than 87.7%, leading to significant losses for investors. Shareholders are encouraged to register for the lawsuit, marking a key deadline of April 6, 2026, for those interested in serving as lead plaintiffs.
Read more →MREOMereo BioPharma Group plc Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – MREO
Mereo BioPharma Group plc is facing a class action lawsuit due to allegations that it misled investors about the efficacy of its Phase 3 ORBIT and COSMIC clinical trials. The complaint states that the company provided overly positive statements while concealing negative facts regarding trial outcomes, both of which failed to meet statistical significance. Following this revelation, Mereo's stock price experienced a steep decline, falling more than 87.7%. The Gross Law Firm is encouraging affected shareholders to register for potential recovery.
Read more →MREO▼ -8.5%on this news
MEREO LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Mereo BioPharma Group plc and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against Mereo BioPharma Group plc by Bragar Eagel & Squire, P.C. on behalf of investors who acquired Mereo American Depositary Shares between June 5, 2023, and December 26, 2025. The lawsuit alleges that the company misled investors regarding the expected results from the Phase 3 ORBIT and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Following the recent announcement that the studies did not meet their primary endpoints, Mereo's stock price saw a significant decline of over 87.7% within a few days. Investors have until April 6, 2026, to apply to be appointed as lead plaintiffs in the case.
Read more →MREO▲ +14.7%on this news· ran to +36% by day 3
Mereo BioPharma Provides Corporate Update
Mereo BioPharma recently provided a corporate update regarding its pipeline and financial situation. The company continues to analyze data from the Phase 3 Orbit and Cosmic studies of setrusumab for osteogenesis imperfecta, despite not achieving statistical significance in primary endpoints. Mereo's cash reserves are projected to fund operations until mid-2027, highlighting its financial stability. Additionally, discussions for potential partnerships for its programs, including alvelestat for alpha-1 antitrypsin deficiency, are ongoing.
Read more →MREO▲ +12.5%on this news· ran to +38% by day 1
Mereo BioPharma Provides Corporate Update Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential path forward for the program Cash b
Mereo BioPharma provided an update on its programs including setrusumab, currently undergoing data analysis from Phase 3 studies for osteogenesis imperfecta. The studies showed strong results in secondary endpoints but failed to demonstrate statistical significance in primary endpoints. The company has approximately $41 million in cash, extending its operational runway to mid-2027. Mereo is also in discussions for partnering opportunities for its other program, alvelestat, aimed at addressing alpha-1 antitrypsin deficiency-associated lung disease.
Read more →MREO▼ -87.6%on this newsshared move
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
Mereo BioPharma announced that its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta did not meet their primary endpoints of reducing clinical fracture rates. However, both studies showed significant improvements in bone mineral density. The company plans to conduct further analyses to determine the next steps for the program, especially in pediatric patients.
Read more →MREO▲ +5.6%on this news
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
Mereo BioPharma reported its Q3 2025 financial results, highlighting progress in Phase 3 studies of setrusumab for osteogenesis imperfecta, expected to conclude by the end of 2025. The company has $48.7 million in cash, projected to fund operations through 2027. Despite a net loss of $7.0 million, Mereo remains optimistic about its product pipeline and commercial readiness.
Read more →MREO▲ +9.2%on this news
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $5
Mereo BioPharma reported its Q2 2025 financial results, highlighting its ongoing clinical studies for setrusumab in osteogenesis imperfecta and plans for alvelestat in AATD-lung disease. The company has a solid cash position to support operations until 2027, amid recent announcements regarding upcoming data from pivotal trials. While it demonstrated increased R&D expenses, Mereo maintains optimism due to the potential impact of its product candidates and ongoing discussions for potential partnerships.
Read more →MREO▼ -7.2%on this news
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of
Mereo BioPharma reported its first quarter 2025 financial results, highlighting the ongoing Phase 3 Orbit study for setrusumab in osteogenesis imperfecta. As of March 31, 2025, the company holds $62.5 million in cash, which is anticipated to fund operations into 2027. The company is also preparing for a potential launch of setrusumab in Europe and is advancing alvelestat towards a Phase 3 pivotal study after receiving Orphan Designation from the European Commission. Despite these developments, Mereo reported a net loss of $12.9 million for the quarter.
Read more →MREOMereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvele
Mereo BioPharma reported its financial results for the full year 2024 and outlined significant advancements in its clinical studies. The Phase 3 Orbit study for setrusumab in osteogenesis imperfecta is progressing towards a second interim analysis expected in mid-2025. Additionally, alvelestat received Orphan Designation from the European Commission for treating alpha-1 antitrypsin deficiency-associated lung disease. The company reported a net loss of $43.3 million while maintaining a strong cash position that supports operations into 2027.
Read more →MREOMereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
Mereo BioPharma announced that CEO Dr. Denise Scots-Knight will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 12, 2025. The company focuses on developing therapeutics for rare diseases, with key candidates including setrusumab and alvelestat. Mereo's partnerships and designations from regulatory bodies highlight its commitment to innovation in the biopharmaceutical sector.
Read more →MREO▼ -5.9%on this news· ran to -18% by day 3
Mereo BioPharma Provides Update on Lead Clinical Programs
Mereo BioPharma has provided updates on its lead clinical programs, including the Phase 3 Orbit study of setrusumab for osteogenesis imperfecta, which is progressing towards a second interim analysis expected in mid-2025. Additionally, alvelestat received a positive opinion for European Orphan Designation, with a final decision anticipated in early 2025. The company maintains a strong cash position to support operations through 2027.
Read more →MREOMereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mereo BioPharma will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company focuses on developing therapeutics for rare diseases, with notable candidates including setrusumab and alvelestat. Mereo's partnerships and designations from regulatory bodies highlight its commitment to advancing its product pipeline.
Read more →MREO▼ -5.7%on this news
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Mereo BioPharma Group plc (NASDAQ: MREO) announced that Dr. Denise Scots-Knight, CEO, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on November 19, 2024. The event aims to address their advancements and strategies in the rare diseases sector. Investors can access a live audio webcast of the presentation through the company's website, and an archived replay will be available for two weeks following the event.
Read more →MREOMereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of
Mereo BioPharma reported its financial results for Q3 2024, highlighting significant developments including the FDA's Breakthrough Therapy designation for setrusumab, targeting osteogenesis imperfecta. The company has $80.5 million in cash reserves, expected to sustain operations into 2027. Despite an increase in net loss primarily due to foreign exchange impacts, the Phase 3 programs for setrusumab and alvelestat remain on track for further advancements. The company continues to establish its presence in key European markets with ongoing pre-commercial activities.
Read more →MREO▼ -5.8%on this news
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
Mereo BioPharma Group plc announced that its CEO, Dr. Denise Scots-Knight, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on September 18, 2024. The live audio webcast will be accessible via the company's investors section on their website. Mereo is focused on developing treatments for rare diseases, with notable progress in candidate products such as setrusumab and alvelestat. The company has ongoing partnerships and has received various designations for its products from regulatory agencies.
Read more →MREOMereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2
Mereo BioPharma reported its second quarter 2024 financial results, highlighting significant advances in its clinical studies for setrusumab in osteogenesis imperfecta (OI), with a documented 67% reduction in fracture rates. The company has secured $87.4 million in cash, projected to sustain operations through 2027. Mereo continues to prepare regulatory submissions for its alvelestat program to ensure compliance for Phase 3 readiness by year's end. However, R&D expenses have noticeably increased, leading to a higher net loss this quarter compared to last year.
Read more →MREO▲ +6.5%on this news
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market London
Mereo BioPharma has announced the pricing of an underwritten registered direct offering of 12,531,300 American Depositary Shares at a price of $3.99 each, aiming to raise approximately $50 million. The funds will primarily be allocated to support the setrusumab program and general corporate purposes. The offering, expected to close around June 17, 2024, includes participation from several institutional investors. This offering helps bolster the company’s financial position as it progresses with its clinical development plans for rare disease therapies.
Read more →MREOUltragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfect
Ultragenyx and Mereo BioPharma have announced positive results from the Phase 2 portion of their Orbit study, indicating that treatment with setrusumab (UX143) led to a significant 67% reduction in annualized fracture rates among patients with Osteogenesis Imperfecta. After 14 months of treatment, continued improvements in bone mineral density were noted, with a mean increase of 22%. No serious adverse events related to the treatment were observed, and further data presentations are anticipated in the future.
Read more →MREO▲ +5.9%on this news
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Mereo BioPharma Group plc announced that its CEO, Dr. Denise Scots-Knight, will participate in the Jefferies Global Healthcare Conference on June 6, 2024. The conference will feature a live audio webcast accessible on the company's investor website, with an archived replay available for two weeks afterward. Mereo BioPharma is focused on developing innovative therapeutics for rare diseases, with ongoing clinical programs for two product candidates, setrusumab and alvelestat, which have received several regulatory designations. The company is also engaged in oncology development and has established partnerships to enhance its product pipeline.
Read more →MREO▲ +7.1%on this news
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update London
Mereo BioPharma has reported its financial results for the first quarter of 2024, showing a cash balance of $48.7 million, sufficient to fund operations until 2026. The company has made significant progress with its product candidate setrusumab, completing patient enrollment in ongoing studies. Additionally, R&D expenses have decreased, reflecting better financial management and operational efficiency. However, the company still faces a net loss that has increased year-over-year, and its reliance on third-party funding and clinical development uncertainties present ongoing challenges.
Read more →MREOMereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Mereo BioPharma Group plc announced that CEO Dr. Denise Scots-Knight will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference scheduled for April 9, 2024. The event aims to provide insights into Mereo's clinical-stage biopharmaceutical focus on developing innovative therapeutics for rare diseases. Mereo has two notable product candidates in the pipeline and has established valuable partnerships, enhancing its potential market performance. Additionally, live audio webcast access for the event will be available on the company's website.
Read more →MREOMereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the en
Mereo BioPharma has reported its financial results for the full year 2023, announcing that its Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab are on track for enrollment completion in the upcoming quarters. The company highlighted its strong cash position of $57.4 million, which is expected to sustain operations until 2026. Additionally, Mereo is discussing partnerships for alvelestat, with plans for a Phase 3 study expected to initiate by the end of 2024. Despite a net loss of $29.5 million reported for 2023, the company remains optimistic about future developments.
Read more →MREOMereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
Mereo BioPharma Group plc announced that its CEO, Dr. Denise Scots-Knight, will participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference scheduled for March 12, 2024. This participation reflects the company's focus on increasing visibility and confidence in its clinical-stage biopharmaceutical operations, particularly in rare diseases. Mereo has ongoing collaborations with Ultragenyx Pharmaceuticals and has made advancements in its product development pipeline, notably for osteogenesis imperfecta and Alpha-1 Antitrypsin Deficiency-associated lung disease.
Read more →MREOMereo BioPharma Provides Update on Pipeline Progress and Corporate Developments Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ult
Mereo BioPharma has provided a comprehensive update on its pipeline progress and corporate developments. The Phase 3 studies for setrusumab in treating Osteogenesis Imperfecta are set to complete enrollment around Q1 and Q2 of 2024, following promising Phase 2 results. The company also advanced its alvelestat program, with guidance from regulators indicating a potential primary endpoint for future studies. Financially, Mereo expects to have sufficient cash reserves to fund operations through 2026.
Read more →MREO▼ -6.4%on this news
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this notice or as to the action you should take, please take advice from a stockb
Mereo BioPharma Group plc has issued a notice for a General Meeting scheduled for December 18, 2023, at 2:00 p.m. UK time. The notice includes details on proxy voting procedures, urging shareholders to submit their votes electronically or via hard copy. Shareholders must ensure that proxy appointments are submitted by December 14, 2023, or 48 hours prior to any adjourned meetings. This document highlights the necessity of shareholder participation and provides important contact information for assistance.
Read more →MREO▼ -7.9%on this news
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update London
Mereo BioPharma Group plc provided an update on its recent program developments and third quarter financials. The company reported significant interim results for setrusumab in reducing fracture rates in osteogenesis imperfecta and positive safety data for alvelestat in treating lung disease. Additionally, etigilimab showed promising efficacy in a Phase 1b/2 trial for solid tumors. Financially, Mereo held cash reserves that are expected to support operations and clinical trials into 2026.
Read more →MREO▲ +24%on this news· ran to +40% by day 3
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) Phase 2 data pre
Ultragenyx and Mereo BioPharma have announced positive interim results from the Phase 2 portion of the Phase 2/3 Orbit study for Setrusumab (UX143) in patients with Osteogenesis Imperfecta (OI). The data revealed a significant 67% reduction in fracture rates among patients receiving the treatment, alongside meaningful increases in bone mineral density. The companies are preparing to discuss these findings further during an Analyst Day event. Currently, the Phase 3 study is ongoing, enrolling approximately 195 patients across 50 sites globally.
Read more →MREO▼ -5.7%on this news
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
Mereo BioPharma Group plc announced that CEO Dr. Denise Scots-Knight will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on September 27, 2023. The company, known for developing treatments for rare diseases, has ongoing clinical trials for its product candidates, including setrusumab and alvelestat. Mereo has partnerships for these product candidates, which include potential milestone payments and royalties. The event will be accessible via webcast on the company's website.
Read more →MREOMEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive Loss (unaudited) Notes Six months ended
Mereo BioPharma Group PLC released its unaudited financial statements for the six months ending June 30, 2023. The company reported a significant operating loss of £9,909,000, though this is an improvement compared to £21,810,000 for the same period in 2022. Mereo's research and development expenses decreased but still represent a substantial cost. Overall, while the company saw some revenue generation, its net losses remain a concern.
Read more →MREOMereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
Mereo BioPharma reported its interim financial results for the first half of 2023, highlighting significant developments in its rare disease programs. The company announced positive data from the Phase 2 Orbit study of setrusumab in osteogenesis imperfecta and received clear regulatory guidance for alvelestat's Phase 3 study design. Mereo's cash reserves are sufficient to fund operations into 2026, following a $9 million milestone payment from Ultragenyx. Despite a net loss of £11 million, Mereo is making strides in its clinical trials and partnerships.
Read more →MREOUltragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatri
Ultragenyx Pharmaceutical Inc. has announced the dosing of the first patients in two Phase 3 clinical trials evaluating setrusumab (UX143) for osteogenesis imperfecta (OI) in pediatric and young adult patients. The trials, part of the Orbit study and a newly initiated Cosmic study, aim to assess the drug's effectiveness on clinical fracture rates. Positive results from the Phase 2 portion have encouraged the company, indicating improvements in bone density and formation. The comprehensive Phase 3 program, involving collaboration with Mereo BioPharma, seeks to gather more data on the potential benefits of setrusumab for young patients with OI.
Read more →MREOUltragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) Pediatric data show substantial induction of bone production in 1 week an
Ultragenyx and Mereo BioPharma have released positive data from the Phase 2/3 Orbit study of Setrusumab (UX143) for treating Osteogenesis Imperfecta (OI). The results indicate a substantial increase in bone production and density among pediatric patients within a short treatment duration. Additionally, the Phase 3 trial is underway with patient screening already in progress. The favorable safety profile observed suggests the potential for further advancements in OI treatment.
Read more →MREOMereo BioPharma to Present at the Jefferies Healthcare Conference
Mereo BioPharma Group plc announced that its CEO, Dr. Denise Scots-Knight, will present at the Jefferies Healthcare Conference on June 8, 2023. The company is focused on developing therapeutics for rare diseases, with product candidates including setrusumab and alvelestat. Mereo has received significant FDA designations for alvelestat and has established partnerships that include potential lucrative milestones. This presentation highlights the company’s ongoing commitment to addressing rare diseases and its growth strategy.
Read more →MREOMereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement London
Mereo BioPharma Group plc announced that it has regained compliance with the Nasdaq minimum bid price requirement, having maintained a share price of $1.00 or more for at least 10 consecutive trading days. This achievement comes after previously receiving a notification from Nasdaq regarding non-compliance in November 2022. The company is focused on developing innovative therapeutics for rare diseases and has established partnerships that include substantial milestone payment potential.
Read more →MREOMereo BioPharma Announces Listing Transfer to Nasdaq Capital Market London
Mereo BioPharma recently announced its transfer of listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective May 3, 2023. The company met all necessary market value requirements for this transition but must remain compliant with the bid price rule for its American Depositary Shares (ADSs). The company has successfully exceeded the minimum bid price requirement and is positioned to continue its operations without interruption under the same ticker symbol, MREO. Mereo is focused on developing therapeutics for rare diseases and has partnered with Ultragenyx Pharmaceutical on key product candidates.
Read more →MREOMereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
Mereo BioPharma Group plc (NASDAQ: MREO) will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference on April 20, 2023. The event will feature Dr. Denise Scots-Knight, CEO, alongside other management team members. Investors can access a live audio webcast, with an archived replay available for two weeks thereafter. Mereo has a focus on developing therapeutics for rare diseases and has several promising clinical candidates in its pipeline.
Read more →MREOMereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights London
Mereo BioPharma Group plc reported its financial results for 2022, indicating progress in its rare disease programs. The Phase 2 ASTRAEUS study data for alvelestat showed promise, supporting discussions with regulatory agencies for future approvals. The company concluded the year with a solid cash position of $68.2 million, projecting enough financial runway to sustain operations until 2026. However, it recorded a significant net loss compared to the previous year, driven by increased R&D expenses.
Read more →MREO▲ +16.9%on this news
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1- Antitrypsin Deficiency-Associated Lung Disease Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 24
Mereo BioPharma announced regulatory updates regarding alvelestat, aimed at treating alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD). Following discussions with the FDA and EMA, the company has established a clear pathway for a single Phase 3 study evaluating alvelestat against placebo, which is designed to support full marketing approvals in both the U.S. and the EU. The meeting yielded positive feedback regarding the study's design, which includes patient-reported outcomes and CT scan assessments as primary endpoints. The company aims to enroll around 200 patients over 12-18 months without necessitating additional studies for confirmation.
Read more →MREOMereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
Mereo BioPharma Group plc has announced that its CEO, Dr. Denise Scots-Knight, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023. This event underscores Mereo's strategic positioning within the biopharmaceutical industry, particularly in rare diseases and oncology. The company is advancing a robust pipeline of clinical-stage therapeutics, including setrusumab and alvelestat, with ongoing partnerships that enhance its potential for growth and revenue generation.
Read more →MREO▼ -7%on this news
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency LONDON
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency LONDON, Nov. 2, 2022 (GLOBE NEWSWIRE) Mereo BioPharma Group plc (NASDAQ: MREO), ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announc
Read more →MREO▼ -7%on this news
MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive (Loss)/Income (unaudited) Notes Six months ended
MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive (Loss)/Income Notes Six months ended June 30, 2022 '000 Six months ended June 30, 2021 '000 Revenue 3 - 36,464 Cost of revenue 3 352 ( 18,137 ) Research and development expenses
Read more →MREOMereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management Mereo to Appoint Four New Directors to its Board of Directors Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management Mereo to Appoint Four New Directors to its Board of Directors Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo s 2024 Ann
Read more →MREOMereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:0
Read more →MREOMereo BioPharma Files Shareholder Circular for Upcoming General Meeting Reiterates Quality and Composition of Mereo s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo s Strategy and
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting Reiterates Quality and Composition of Mereo s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo s Strategy and Maximize Shareholder Value Details Rubric s Rejection of
Read more →MREOMereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Crea
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Reiterates Commitment to Disciplined Capital Allocation and Ma
Read more →MREOMereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease Designation Validates Alvelestat s Potential to Address a Serious Unmet Ne
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease Designation Validates Alvelestat s Potential to Address a Serious Unmet Need Company Plans R&D Update on Alvelestat in AATD-associa
Read more →MREOMereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders Rubric has Rejected Mereo s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Camp
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders Rubric has Rejected Mereo s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control Mereo Reiterates Support for its
Read more →MREOMereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer Rubric s Second General Meeting Requisition Notice Again
Read more →MREOMereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in S
Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors Data support further evaluation of PVR, CD226,
Read more →MREOMereo BioPharma Sends Letter to Rubric Capital Management Letter Reiterates Mereo s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric s Assumptions Announces Further Extension of Cash Runw
Mereo BioPharma Sends Letter to Rubric Capital Management Letter Reiterates Mereo s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric s Assumptions Announces Further Extension of Cash Runway into Q2 2025 LONDON August 31, 2022 Mereo BioPharma Gr
Read more →MREOMereo BioPharma Sends Letter to Rubric Capital Management Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders LONDON
Mereo BioPharma Sends Letter to Rubric Capital Management Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders LONDON August 22, 2022 Mereo BioPharma Group plc (NASDAQ: MREO), ( Mereo or the Company ), a clinical-stage biop
Read more →MREOMereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement London and Mountain View, CA
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement London and Mountain View, CA, July 05, 2022 Mereo BioPharma Group plc (NASDAQ: MREO), ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today a
Read more →MREO▼ -5.1%on this news· ran to +19% by day 3
Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan ACTIVATE include
Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan ACTIVATE includes 2 Complete Responses, 4 Partial Responses and 10 patien
Read more →MREOMereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
LONDON and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that on May 23, 2022, it received a notificati
Read more →MREOMereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting Phase 1b/2 Study of Etigilimab and Nivolumab i
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Sol
Read more →MREOMereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors London and Redwood City, Calif.
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors London and Redwood City, Calif., May 17, 2022 - Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on oncology and rare diseases,
Read more →MREO▼ -31.3%on this news
Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from ASTRAEUS Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema Statistically significant inhibition of blood neutroph
Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from ASTRAEUS Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose
Read more →MREOMereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
LONDON and REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a conference call on Monday, May 9,
Read more →MREOMereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive
Read more →MREO▲ +7.7%on this news
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights London and Redwood City, Calif.
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights London and Redwood City, Calif., March 31, 2022 - Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on oncology and rare diseases,
Read more →MREO▼ -10.4%on this news
Disclaimer This presentation has been prepared by Mereo BioPharma Group plc (the "Company") solely for your information and for the purpose of providing background information on the Company, its business and the industr
Mereo BioPharma Group plc NASDAQ: MREO March 14 2022 Alvelestat (MPH966) R&D Day Exhibit 99.1 Disclaimer This presentation has been prepared by Mereo BioPharma Group plc (the "Company") solely for your information and for the purpose of providing background information on the
Read more →MREOMereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022
LONDON and REDWOOD CITY, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a virtual R&D Day on Monday, Mar
Read more →MREOMereo BioPharma Announces Appointment of Anne Hyland to Board of Directors London and Redwood City, Calif.
Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors London and Redwood City, Calif., March 1, 2022 - Mereo BioPharma Group plc (NASDAQ: MREO), Mereo or the Company , a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today a
Read more →MREO▼ -6.7%on this news
Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference
LONDON and REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive
Read more →MREOUAB and Mereo Announce Positive Top-line Results from COSTA a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease Alvelestat reported safe and well-tolerated in patients wit
UAB and Mereo Announce Positive Top-line Results from COSTA a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease Alvelestat reported safe and well-tolerated in patients with COVID-19 Alvelestat, on top of standard of care resulte
Read more →MREOMereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors One complete response, one partial response and four cases of
Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficac
Read more →MREOMereo BioPharma to Present at Two Upcoming Investor Conferences
LONDON and REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive
Read more →MREOMEREO BIOPHARMA GROUP PLC Condensed Consolidated Statement of Comprehensive Income (unaudited) Notes Six months ended
MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statement of Comprehensive Income Notes Six months ended June 30, 2021 '000 Six months ended June 30, 2020 '000 Revenue 3 36,464 - Cost of revenue ( 18,137 ) - Research and development expenses ( 9,
Read more →MREOMereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency London and Redwood City, Calif.
Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency London and Redwood City, Calif., October 26, 2021 - Mereo BioPharma Group plc (NASDAQ: MREO), Mereo or the Company , a clinical stage biopharmaceutical compa
Read more →MREOMereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment
Living With Osteogenesis IMPerfecta: UnderstAnding Experiences Based On Community InsighT and Evidence Survey, the IMPACT Survey More than 2200 individual responses collected over a 3-month period from some 65 countries in 8 languages Set to be the largest global gathering of d
Read more →MREO▲ +7%on this news
Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting Previou
Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting Previously reported data demonstrated dose-dependent, statistica
Read more →MREO▼ -5.3%on this news
Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors LONDON and
Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), Mereo or the Company , a clinical-stage biopharmaceutical company focused on
Read more →MREOMereo BioPharma to Participate in Three Upcoming Investor Conferences
LONDON and REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced senior management’s participation in three up
Read more →MREOMereo BioPharma to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference
LONDON and REDWOOD CITY, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive
Read more →MREOMereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS) London and Redwood City, Calif.
Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS) London and Redwood City, Calif., June 2, 2021 - Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or
Read more →MREOMereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
LONDON and REDWOOD CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive O
Read more →MREOMereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021
LONDON and REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a virtual R&D day on Thursday, May
Read more →MREOMereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer Study to be Conducted at The University of Texas MD Anderson Cancer Center London, UK, Redwood Ci
Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer Study to be Conducted at The University of Texas MD Anderson Cancer Center London, UK, Redwood City, Calif. and Houston, Texas, April 30, 2021 - Mereo BioP
Read more →MREOMereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
LONDON and REDWOOD City, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Company management will present at the 2
Read more →MREOMereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta Further Strengthened Management Team OncXerna Global
Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta Further Strengthened Management Team OncXerna Global Licensing Agreement for Navicixizumab Strengthened Bala
Read more →MREOMereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive
Read more →MREOMereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters Option to Purchase Additional American Depositary Shares LONDON and
Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters Option to Purchase Additional American Depositary Shares LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) Mereo BioPharma Group plc (NAS
Read more →MREOMereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares
LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the pricing of an underwritten public offering
Read more →MREOMereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares London and Redwood City, Calif.
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares London and Redwood City, Calif., February 9, 2021 Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on oncology and rar
Read more →MREOMereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx’s existing bone franchise Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest of world
Read more →MREOTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. Mereo BioPharma
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. Mereo BioPharma and Ultragenyx Announce Collaboration and License Agree
Read more →MREOMereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos Capital London and Redwood City, Calif.
Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos Capital London and Redwood City, Calif., December 15, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (
Read more →MREOMereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
LONDON and REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announces the appointment of Suba Krishnan, M.
Read more →MREOMereo BioPharma to Hold Virtual R&D Day on Tuesday
Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020 London and Redwood City, Calif., November 16, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) ( Mereo or the Company ), a clinical stage biopharmaceutical company focused on oncology and rare diseas
Read more →MREOTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN NOT FOR RELEASE,
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTL
Read more →MREOMereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference
LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief
Read more →MREOMereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs London and Redwood City, Calif.
Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs London and Redwood City, Calif., October 20, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) ( Mereo or the Company ), a clinical stage bi
Read more →MREOMereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)
On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020 Plans to host virtual R&D day to review etigilimab development program and rare disease product pipeline in November 2020 LONDON and REDWOOD CITY, C
Read more →MREOMereo BioPharma Group plc PDMR Notification London and Redwood City, Calif .
Mereo BioPharma Group plc City, Calif., October 12, 2020 Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company , a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on October 09, 2020, Charles Sermon,
Read more →MREOMereo BioPharma Group plc Director and PDMR Dealings London and Redwood City, Calif .
Mereo BioPharma Group plc Director and PDMR Dealings Redwood City, Calif., October 9, 2020 Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company , a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on
Read more →MREOMereo BioPharma Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission and Enters into At-The-Market Sales Agreement with SVB Leerink London and Redwood City, Calif., October 7 , 20 20 On
Mereo BioPharma Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission and Enters into At-The-Market Sales Agreement with SVB Leerink London and Redwood City, Calif., October 7, 2020 On October 6, 2020, Mereo BioPharma Group plc (NASDAQ: MREO, AI
Read more →MREOMereo BioPharma Announces Interim Financial Results for the Six Months Ended
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020 Enrolment resumed in Phase 2 study of alvelestat in Alpha-1 Antitrypsin
Read more →MREOMereo BioPharma Group plc ( Mereo or the Company or the Group ) Result of General Meeting London and Redwood City, Calif.
Mereo BioPharma Group plc ( Mereo or the Company or the Group ) Result of General Meeting and Redwood City, Calif., September 28, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company , a clinical-stage biopharmaceutical company focused on oncology an
Read more →MREOMereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
LONDON and REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces that the U.S. Food and Drug Administ
Read more →MREOMereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call on September 29, 2020
LONDON and REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces that it will release interim financi
Read more →MREOMereo BioPharma Group plc Notice of General Meeting London and Redwood City, Calif.
Mereo BioPharma Group plc Notice of General Meeting London and Redwood City, Calif., September 4, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company , a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces
Read more →MREOMereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
LONDON and REDWOOD CITY, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the initiation of a Phase 1b/2 placeb
Read more →MREOMereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development
LONDON and REDWOOD CITY, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointments of John Lewicki, PhD
Read more →MREOMereo BioPharma Group plc ( Mereo or the Company or the Group ) Result of Annual General Meeting London and Redwood City, Calif.
Mereo BioPharma Group plc ( Mereo or the Company or the Group ) Result of Annual General Meeting London and Redwood City, Calif., June 29, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company , a clinical-stage biopharmaceutical company focused on o
Read more →MREOMereo BioPharma Announces Financial Results for the Year Ended December 31, 2019
LONDON and REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial results for the 12 months e
Read more →MREOPublication of Circular and Notice of General Meeting London and Redwood City, Calif.
Publication of Circular and Notice of General Meeting London and Redwood City, Calif., June 9, 2020 Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) announces that, further to the announcement regarding the completed Private Placement of $70 million ( 56 million) (the Fundrai
Read more →MREOMereo BioPharma Announces Completion of $70 Million Private Placement
LONDON and REDWOOD CITY, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) today announces the completion of a $70 million (£56 million) private placement (the “Fundraising”) with a number of new and existing U.S based institutional and
Read more →MREONotice of Annual General Meeting London and Redwood City, Calif.
Notice of Annual General Meeting London and Redwood City, Calif., May 27, 2020 Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) Mereo or the Company , a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces, as per its Annual General
Read more →MREOAnnual General Meeting London and Redwood City, Calif.
Annual General Meeting City, Calif., May 22, 2020 Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) Mereo or the Company , a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announces that it will be holding its Annual General Meeting ( AGM ) on
Read more →MREOTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. Business Update
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. Business Update and Directorate Change London and Redwood City, Calif.,
Read more →MREOMereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
LONDON and REDWOOD CITY, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced the successful completion of a Type B End-of-Phase
Read more →MREOMereo BioPharma Group plc ( Mereo or the Company ) Notification of Director and other PDMR Dealings London
Mereo BioPharma Group plc ( Mereo or the Company ) Notification of Director and other PDMR Dealings London, February 20, 2020 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, on February 20, 20
Read more →MREOMereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
LONDON and REDWOOD CITY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it has entered into a Securities Purchase Agreement (the “Agreement”) with a new U.S.-based institutional healthca
Read more →MREOUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF MEREO BIOPHARMA GROUP PLC The following unaudited pro forma condensed combined financial information is comprised of the Unaudited Pro Forma Condensed Combi
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF MEREO BIOPHARMA GROUP PLC The following unaudited pro forma condensed combined financial information is comprised of the Unaudited Pro Forma Condensed Combined Statement of Operations for the year ended December 3
Read more →MREOMEREO BIOPHARMA ANNOUNCES UPDATE ON DISTRIBUTION RELATED TO CONTINGENT VALUE RIGHTS FOLLOWING RECENT ONCOLOGIE LICENSING AGREEMENT FOR NAVICIXIZUMAB London and Redwood City, Calif.
MEREO BIOPHARMA ANNOUNCES UPDATE ON DISTRIBUTION RELATED TO CONTINGENT VALUE RIGHTS FOLLOWING RECENT ONCOLOGIE LICENSING AGREEMENT FOR London and Redwood City, Calif., February 12, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company, today announced
Read more →MREOMereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million
LONDON and REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a $5 million convertible
Read more →MREOMereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
Additional Data Demonstrate Dose-Dependent Increase in Bone Strength Stiffness and Failure Load at the Radius as Measured by Finite Element Analysis, a Second Prespecified Primary Endpoint, Reaching Statistical Significance in High Dose Cohort Statistically Significant Increase
Read more →MREOMereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
Oncologie receives exclusive global license to develop and commercialize navicixizumab LONDON, and REDWOOD CITY, Calif., and BOSTON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," and Oncologie, Inc. (“Oncologie”)
Read more →MREOTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN Mereo BioPharma
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN Mereo BioPharma s Setrusumab Demonstrates Dose-Dependent Bone Building an
Read more →MREOMereo BioPharma’s Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta
Dose-Dependent and Statistically Significant Improvement in Areal Bone Mineral Density (BMD) Over Baseline at the Lumbar Spine, as Measured by DXA, Reaching 8.8% at 12 Months in Highest Dose Cohort (p<0.001); Improvement Consistent Across All OI Subtypes Represented in Study Tre
Read more →MREOMereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer London and Redwood City, Calif.
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer London and Redwood City, Calif., October 7, 2019 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company or the Group, a clinical stag
Read more →MREOMereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019
LONDON and REDWOOD CITY, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical company focused on rare diseases, today announces that it will release interim finan
Read more →MREOMereo BioPharma Announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta Selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting
LONDON and REDWOOD CITY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical company focused on rare diseases, today announces that the 6-month interim data from
Read more →MREOMereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
LONDON and REDWOOD CITY, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today announces the appointment of Richard Francis as Head of Pharmaceutical Development, ef
Read more →MREOMereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Mereo Bi
Read more →MREOMereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Update on Etigilimab (TIGIT) Partnership
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- Mereo Bi
Read more →MREOMereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)
Clear and encouraging percentage changes over baseline in trabecular volumetric bone mineral density measured at the radius at an early readout Expect topline 12 month data from the blinded arms of study to be available in fourth quarter 2019 A call for analysts and investors w
Read more →MREOMereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Intention to Purchase Shares by Trustee of Employee Benefit Trust
LONDON, May 03, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH, NASDAQ:MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces that the Trustee of the Mereo BioPharma Group plc Employee Benefit Trust (the “Trust”), Link
Read more →MREOMereo BioPharma Group Plc ("Mereo" or the "Company" or the "Group") Preliminary Results for the Year Ended December 31, 2018 -- Strong Operational Progress
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 29, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM:
Read more →MREOMereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announced that it will relea
Read more →MREOMereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary Shares
LONDON, April 24, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces that, in connection with the completed merger with OncoMed Pharmaceuticals, Inc. (“OncoM
Read more →MREOMereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED) have approved the transactions contemplated by the merger a
Read more →MREOMereo BioPharma to Present at the Cowen and Company 39th Annual Healthcare Conference on Tuesday, March 12, 2019
LONDON, March 05, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, is pleased to announce that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Cowen and Com
Read more →MREOMereo Publicly Files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") LONDON, Jan. 25, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that a further step towards the pr
Read more →MREOMereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") LONDON, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, is pleased to announce that Dr. Deni
Read more →Competitive Position
How MREO ranks across every disease it competes inCompetitive Position is a premium feature
See how MREO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial